Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-dose safety study of ZP5-9676 600 mg
PACTR202509752982237Phase 3Not yet recruiting
- Sponsor
- Zero Point Five Therapeutics
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ZP5-9676 in Soil-Transmitted Helminthiases (STH), sponsored by Zero Point Five Therapeutics. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ZP5-9676
03
Conditions
Soil-Transmitted Helminthiases (STH)
Beyond the preview
Go deeper on PACTR202509752982237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202509752982237.